Latest News and Press Releases

Chers Actionnaires, Nous avons le plaisir de vous adresser, en pièce jointe, la Lettre aux actionnaires de GENFIT publiée à l’approche de notre Assemblée Générale Mixte du 15 juin 2026. Cette lettre...

Dear Shareholders, We are pleased to send you, in the attached document, GENFIT’s Shareholders’ Letter published ahead of our Annual General Meeting to be held on June 15, 2026. This letter outlines...

EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...

Austin, TX, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Aesthetics Injectables Market Size, Trends and Insights By Product Type...

NEW YORK, July 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...

GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long...

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership ...